Anruowita Pharmaceutical Taizhou Co., Ltd.

Primary objective: To demonstrate the bioequivalence between the test product (T): Doxazosin Mesylate Tablets 4 mg produced by Anruovita Pharmaceuticals Taizhou Co., Ltd. and the reference product (R): Cardura® (Doxazosin Mesylate) Tablets 4 mg produced by Roerig Division of Pfizer Inc, USA, in 32 healthy, adult, male & female, human subjects under fed conditions. Secondary objective: To monitor the safety and efficacy of single oral doses of investigational products (IPs) in subjects.

Primary objective: To demonstrate the bioequivalence between the test product (T): Doxazosin Mesylate Tablets 4 mg produced by Anruovita Pharmaceuticals Taizhou Co., Ltd. and the reference product (R): Cardura® (Doxazosin Mesylate) Tablets 4 mg produced by Roerig Division of Pfizer Inc, USA, in 32 healthy, adult, male & female, human subjects under fasting conditions. Secondary objective: To monitor the safety and efficacy of single oral doses of investigational products (IPs) in subjects

Primary objective: To demonstrate the bioequivalence of brivudine tablets 125 mg (test formulation) from Anrovita Pharmaceuticals Taizhou Co., Ltd. and Zostex 125 mg (reference formulation) from BERLIN-CHEMIE AG, Germany in healthy, adult, human subjects under fasting conditions. Secondary objective: To monitor the safety and tolerability of a single oral dose of the study drug (IP) in subjects.